InVivo Therapeutics Names Interim Chief Science Officer

InVivo Therapeutics Holdings, a developer of technologies for spinal cord injuries and neurotrauma, appointed Brian Hess as interim chief science officer.

Advertisement

Prior to this appointment, Mr. Hess served as InVivo’s director of product development, a position he has held since February. Before joining InVivo, he spent eight years at Stryker developing biomaterial technologies for the orthopedic market. At Stryker, he was instrumental in leading multiple product development teams through the FDA process and developing HydroSet.

More Articles on Orthopedic Devices:

Titan Spine Awarded Patent

US Soft Tissue Solutions to Grow to $2B

Study: MoM Hip Implants Not Linked to Cancer After 7 Years

Advertisement

Next Up in Spinal Tech

Advertisement

Comments are closed.